A fter treatment, colorectal cancer (CRC) patients often face lifelong challenges in returning to normal life. Two studies reported at January's Gastrointestinal Cancers Symposium show that many CRC survivors, particularly rectal cancer survivors, suffer from bowel function issues every day, even 5-10 years after treatment
In the first study, James Metz, M.D., professor of radiation oncology at the Hospital of the University of Pennsylvania in Philadelphia, presented patientreported outcomes for 657 CRC patients who used a publicly available Internet tool to voluntarily create survivorship care plans (http://www.livestrongcareplans. com). While creating a care plan, users answered questions about side effects associated with treatments: 63% reported chronic changes in bowel movements, 38% reported chronic diarrhea, 9% suffered bowel obstruction, 18% developed a hernia, 8% suffered from radiation colitis, and 2% developed fistulas.
Of 249 users who answered questions regarding degree of gastrointestinal problems, 23% reported having four to six stools per day and 18% reported having more than six stools daily or incontinence. Thirty-five percent of men had decreased erectile function and 42% of women reported vaginal dryness.
Although the data did not parse colon cancer patients from rectal cancer patients, using radiation therapy as a surrogate for rectal cancer patients, "changes in bowel patterns were more common in patients who had had rectal cancer, although still reported by over a third of those with colon cancer," Metz said. Incidence of sexual changes was similar in the two groups, regardless of whether patients had received pelvic irradiation. Radiation colitis and fistula formation, however, were unique to the rectal cancer population, he added. 
FDA Considers Restricting or Banning Laparoscopic Morcellation
By Vicki Brower T he U.S. Food and Drug Administration is considering restricting or banning morcellation in minimally invasive hysterectomies and myomectomies (removal of fibroids) because of new reports of higher incidence of undiagnosed sarcoma in women undergoing these procedures. Research now links morcellation to the spread, or upstaging, of undetectable gynecological cancers. In July, FDA convened a 2-day Obstetrics and Gynecology Devices Advisory Committee meeting to discuss risks and benefits of morcellation and to determine ways to reduce risk of upstaging cancers.
In December 2013, after receiving the first report of an upstaged cancer due to morcellation, FDA sent out a safety communication to discourage morcellation in laparoscopic gynecologic surgeries. Women whose cancers upstaged after morcellation live a median of 11.5 months after the procedure. About 50,000 U.S. women per year undergo morcellation. Other risks include visceral and vascular injuries, Craig J. Sobolewski, M.D., assistant professor at Duke University in Durham, N.C., said at the meeting. Owing to the report and the FDA warning, several U.S. medical centers have stopped using laparoscopic power morcellation (LPM), and Johnson & Johnson's Ethicon device subsidiary has stopped marketing its morcellator.
Previously thought to be much rarer, uterine sarcomas, and especially leiomyosarcomas, are lethal and virtually impossible to detect. In April, FDA increased the estimate of sarcoma risk for women undergoing hysterectomy or myomectomy for presumed fibroids from between 1 in 500 and 1 in 10,000 to about 1 in 352 for unsuspected uterine sarcomas, and 1 in 498 for leiomyosarcomas. The most recent study, by Jason Wright, M.D., chief of gynecologic oncology at Columbia University in New York, found that cancer risk in women undergoing hysterectomy for symptomatic fibroids is 1 in 370 (JAMA online, July 22, 2014). The study also detected other malignancies and precancerous abnormalities.
"Although morcellators [surgical instruments that assist in laparoscopic surgery] have been in use since 1993, few studies have described the prevalence of unexpected pathology at the time of hysterectomy," the authors wrote. "Prevalence information is the first step in determining the risk of spreading cancer with morcellation," they noted.
Patients considering morcellation should be adequately counseled about the prevalence of cancerous and precancerous lesions, Wright said. After a period of public comment on the July meeting and the participation of surgeons and other experts, patients, and their families, FDA will issue its decision about whether to restrict or ban morcellation.
Years of Morcellation
LPM uses a morcellator to slice tissue into small pieces, enabling surgeons to remove the uterus and fragments of large fibroids without making large incisions. But LPM can lead to complications. The procedure can spread cells and tissue fragments throughout the peritoneal cavity. If benign, these cells can grow and cause adhesions, causing pain and dysfunction. If cancerous, they can lead to inaccurate cancers, bowel cancer has received less attention, Ganz said, because patients are not as accessible.
"They tend to be older and aren't necessarily treated at academic institutions," Ganz said.
Moreover, although many studies identified bowel function as a major issue among CRC survivors, hardly any have looked at how survivors cope, Sun said. She found that patients control bowel movements not only through dietary changes and medication but also through behavioral changes.
"A lot of these issues with bowel function have been well known," Ganz added. "But they have not been integrated into good follow-up care with these patients. Having this kind of research and sharing it with the patient is very powerful in terms of saying we can't ignore it."
Sun is planning follow-up studies. For one, contrary to common belief, patients who received a temporary ostomy after colon cancer surgery reported worse quality of life than patients with a permanent one-she plans to study why. She also hopes to help develop interventions for CRC survivors.
"People do improve on their own over time," Sun said, "but the process is difficult. We want to learn from these studies to develop evidence-based interventions to help survivors adjust and manage bowel function better."
